Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 May;80(5-6):775–785. doi: 10.1038/sj.bjc.6690421

Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion

Y Nio 1, H Nagami 1, K Tamura 1, M Tsubono 2, M Nio 2, M Sato 2, K Kawabata 3, H Hayashi 3, T Shiraishi 4, S Imai 5, T Tsuchitani 6, J Mizuta 7, M Nakagawa 8, M Fukumoto 9
PMCID: PMC2362297  PMID: 10360655

Abstract

The current prospective randomized study was designed to compare the effects of intracavitary (i.c.) chemotherapy vs immunotherapy vs immunochemotherapy for malignant effusion. Between 1992 and 1995, a total of 42 patients with malignant effusion were registered, and 41 patients were eligible for statistical analysis. The primary diseases of the eligible patients included 27 gastric, four colorectal, four pancreatic, three lung, two liver and one oesophageal cancers. The patients with malignant effusion were randomly assigned into one of three i.c. therapeutic regimens: chemotherapy alone with weekly injection of anticancer agents (ACAs: cisplatin, mitomycin-C, adriamycin, etc.) (Group A, n = 13); immunotherapy alone with weekly injection of streptococcal preparation OK-432 (Group B, n = 14); or immunochemotherapy with ACAs and OK-432 (Group C, n = 14). The response of the effusion, patient survival and the kinetics of cytokines in the effusion were compared. There were no differences in the patients' backgrounds. The side-effects of the regimens included pain, anorexia, fever, leucopenia and anaemia and there were no differences in their incidence among the three groups. One patient died after cisplatin (CDDP) administration in Group A. Cytologic examination revealed that tumour cells in the effusion disappeared in 23% of Group A cases, 36% of Group B cases and 36% of Group C cases. The malignant effusion did not disappear in any of the Group A cases; however, the effusion disappeared in 29% of Group B cases and 43% of Group C cases (P = 0.03, Group A vs Group C). Furthermore, the 50% survival period was 1.6 months for Group A, 2.4 months for Group B and 3.5 months for Group C. The 6-month survival rate was 7% for Group A, 6% for Group B and 34% for Group C, and the 1-year survival rate was 0%, 0% and 17% respectively (P = 0.048, Group A vs Group C by the log-rank test). The analysis of the cytokine kinetics revealed a prominent increase in the level of interleukin-6 in the effusion in Group C. These results suggest that i.c. immunochemotherapy with OK-432 and ACAs may be more beneficial than i.c. chemotherapy alone or immunotherapy alone. © 1999 Cancer Research Campaign

Keywords: malignant effusion, chemotherapy, immunotherapy, OK-432 (Picibanil), intracavital therapy

Full Text

The Full Text of this article is available as a PDF (232.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Allavena P., Pirovano P., Bonazzi C., Colombo N., Mantovani A., D'Incalci M. In vitro and in vivo effects of cisplatin on the generation of lymphokine-activated killer cells. J Natl Cancer Inst. 1990 Jan 17;82(2):139–142. doi: 10.1093/jnci/82.2.139. [DOI] [PubMed] [Google Scholar]
  2. Bier H. Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy. II. Chemotherapy and T lymphocyte depression. ORL J Otorhinolaryngol Relat Spec. 1987;49(2):57–66. doi: 10.1159/000275908. [DOI] [PubMed] [Google Scholar]
  3. Bier H., Bier J. Animal experiments on the role of T lymphocytes in the course of antineoplastic chemotherapy. I. Chemotherapy and tumor-specific immunity. ORL J Otorhinolaryngol Relat Spec. 1987;49(1):48–55. doi: 10.1159/000275906. [DOI] [PubMed] [Google Scholar]
  4. Ehrke M. J., Ryoyama K., Cohen S. A. Cellular basis for adriamycin-induced augmentation of cell-mediated cytotoxicity in culture. Cancer Res. 1984 Jun;44(6):2497–2504. [PubMed] [Google Scholar]
  5. Fujita K. The role of adjunctive immunotherapy in superficial bladder cancer. Cancer. 1987 Jun 15;59(12):2027–2030. doi: 10.1002/1097-0142(19870615)59:12<2027::aid-cncr2820591210>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  6. Fukuma K., Matsuura K., Shibata S., Nakahara K., Fujisaki S., Maeyama M. Pseudomyxoma peritonei: effect of chronic continuous immunotherapy with a streptococcal preparation, OK-432 after surgery. Acta Obstet Gynecol Scand. 1986;65(2):133–137. doi: 10.3109/00016348609158368. [DOI] [PubMed] [Google Scholar]
  7. GEHAN E. A. A GENERALIZED WILCOXON TEST FOR COMPARING ARBITRARILY SINGLY-CENSORED SAMPLES. Biometrika. 1965 Jun;52:203–223. [PubMed] [Google Scholar]
  8. George S. L., Desu M. M. Planning the size and duration of a clinical trial studying the time to some critical event. J Chronic Dis. 1974 Feb;27(1):15–24. doi: 10.1016/0021-9681(74)90004-6. [DOI] [PubMed] [Google Scholar]
  9. Goto M., Mitsuoka A., Sugiyama M., Kitano M. Enhancement of delayed hypersensitivity reaction with varieties of anti-cancer drugs. A common biological phenomenon. J Exp Med. 1981 Jul 1;154(1):204–209. doi: 10.1084/jem.154.1.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Heppner G. H., Calabresi P. Suppression by cytosine arabinoside of serum-blocking factors of cell-mediated immunity to syngeneic transplants of mouse mammary tumors. J Natl Cancer Inst. 1972 Apr;48(4):1161–1167. [PubMed] [Google Scholar]
  11. Katano M., Torisu M. Neutrophil-mediated tumor cell destruction in cancer ascites. Cancer. 1982 Jul 1;50(1):62–68. doi: 10.1002/1097-0142(19820701)50:1<62::aid-cncr2820500113>3.0.co;2-0. [DOI] [PubMed] [Google Scholar]
  12. Kawagoe K., Masuda H. Advanced ovarian cancer treated by intraperitoneal immunotherapy with OK-432. Jpn J Clin Oncol. 1986 Jun;16(2):137–142. doi: 10.1093/oxfordjournals.jjco.a039129. [DOI] [PubMed] [Google Scholar]
  13. Kim J. P. The concept of immunochemosurgery in gastric cancer. World J Surg. 1987 Aug;11(4):465–472. doi: 10.1007/BF01655811. [DOI] [PubMed] [Google Scholar]
  14. Kimura I., Ohnoshi T., Yasuhara S., Sugiyama M., Urabe Y. Immunochemotherapy in human lung cancer using the streptococcal agent OK-432. Cancer. 1976 May;37(5):2201–2203. doi: 10.1002/1097-0142(197605)37:5<2201::aid-cncr2820370507>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  15. Kitsuki H., Uchiyama A., Yoshida T., Torisu M. OK-432-induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. Clin Immunol Immunopathol. 1994 Apr;71(1):89–95. doi: 10.1006/clin.1994.1056. [DOI] [PubMed] [Google Scholar]
  16. Kleinerman E. S., Zwelling L. A., Howser D., Barlock A., Young R. C., Decker J. M., Bull J., Muchmore A. V. Defective monocyte killing in patients with malignancies and restoration of function during chemotherapy. Lancet. 1980 Nov 22;2(8204):1102–1105. doi: 10.1016/s0140-6736(80)92540-4. [DOI] [PubMed] [Google Scholar]
  17. Luh K. T., Yang P. C., Kuo S. H., Chang D. B., Yu C. J., Lee L. N. Comparison of OK-432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A randomized trial. Cancer. 1992 Feb 1;69(3):674–679. doi: 10.1002/1097-0142(19920201)69:3<674::aid-cncr2820690313>3.0.co;2-5. [DOI] [PubMed] [Google Scholar]
  18. Maehara Y., Sugimachi K., Akagi M., Kakegawa T., Shimazu H., Tomita M. Early postoperative chemotherapy following noncurative resection for patients with advanced gastric cancer. Br J Cancer. 1992 Mar;65(3):413–416. doi: 10.1038/bjc.1992.84. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Mantovani A., Luini W., Peri G., Vecchi A., Spreafico F. Effect of chemotherapeutic agents on natural cell-mediated cytotoxicity in mice. J Natl Cancer Inst. 1978 Nov;61(5):1255–1261. doi: 10.1093/jnci/61.5.1255. [DOI] [PubMed] [Google Scholar]
  20. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  21. Mizutani Y., Nio Y., Yoshida O. Modulation by cis-diamminedichloroplatinum (II) of the susceptibilities of human T24 lined and freshly separated autologous urinary bladder transitional carcinoma cells to peripheral blood lymphocytes and lymphokine activated killer cells. J Urol. 1992 Feb;147(2):505–510. doi: 10.1016/s0022-5347(17)37289-0. [DOI] [PubMed] [Google Scholar]
  22. Mizutani Y., Nio Y., Yoshida O. The streptococcal preparation OK-432 specifically augments the susceptibility of human urinary bladder tumor cells to autologous peripheral blood lymphocytes. Cancer. 1992 Jun 15;69(12):2999–3007. doi: 10.1002/1097-0142(19920615)69:12<2999::aid-cncr2820691223>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  23. Mukai M., Kubota S., Morita S., Akanuma A. A pilot study of combination therapy of radiation and local administration of OK-432 for esophageal cancer. Five-year survival and local control rate. Cancer. 1995 May 1;75(9):2276–2280. doi: 10.1002/1097-0142(19950501)75:9<2276::aid-cncr2820750914>3.0.co;2-n. [DOI] [PubMed] [Google Scholar]
  24. Nio Y., Ohgaki K., Tobe T. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma. J Clin Lab Immunol. 1989 May;29(1):37–43. [PubMed] [Google Scholar]
  25. Nio Y., Zighelboim J., Berek J. S., Bonavida B. Sensitivity of ovarian tumor cells to effector cells generated by various biological response modifiers. Nat Immun Cell Growth Regul. 1990;9(4):283–296. [PubMed] [Google Scholar]
  26. Nio Y., Zighelboim J., Berek J., Bonavida B. Cytotoxic and cytostatic effects of the streptococcal preparation OK-432 and its subcellular fractions on human ovarian tumor cells. Cancer. 1989 Jul 15;64(2):434–441. doi: 10.1002/1097-0142(19890715)64:2<434::aid-cncr2820640216>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  27. Ogita S., Tsuto T., Tokiwa K., Takahashi T. Intracystic injection of OK-432: a new sclerosing therapy for cystic hygroma in children. Br J Surg. 1987 Aug;74(8):690–691. doi: 10.1002/bjs.1800740812. [DOI] [PubMed] [Google Scholar]
  28. Paladine W., Cunningham T. J., Sponzo R., Donavan M., Olson K., Horton J. Intracavitary bleomycin in the management of malignant effusions. Cancer. 1976 Nov;38(5):1903–1908. doi: 10.1002/1097-0142(197611)38:5<1903::aid-cncr2820380506>3.0.co;2-a. [DOI] [PubMed] [Google Scholar]
  29. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Rusch V. W., Figlin R., Godwin D., Piantadosi S. Intrapleural cisplatin and cytarabine in the management of malignant pleural effusions: a Lung Cancer Study Group trial. J Clin Oncol. 1991 Feb;9(2):313–319. doi: 10.1200/JCO.1991.9.2.313. [DOI] [PubMed] [Google Scholar]
  31. Saito M., Ichimura O., Kataoka M., Moriya Y., Ueno K., Sugawara Y., Nanjo M., Ishida N. Pronounced antitumor effect of LAK-like cells induced in the peritoneal cavity of mice after intraperitoneal injection of OK-432, a killed streptococcal preparation. Cancer Immunol Immunother. 1986;22(3):161–168. doi: 10.1007/BF00200027. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Torisu M., Katano M., Kimura Y., Itoh H., Takesue M. New approach to management of malignant ascites with a streptococcal preparation, OK-432. I. Improvement of host immunity and prolongation of survival. Surgery. 1983 Mar;93(3):357–364. [PubMed] [Google Scholar]
  33. Tsukagoshi S., Sakurai Y., Sato H., Akiba T SUZUKI S. Tumor-inhibitory effect of a streptococcal preparation (NSC-B116209). Cancer Chemother Rep. 1972 Feb;56(1):9–17. [PubMed] [Google Scholar]
  34. Uchida A., Hoshino T. Clinical studies on cell-mediated immunity in patients with malignant disease. I. Effect of immunotherapy with OK-432 on lymphocyte subpopulation and phytomitogen responsiveness in vitro. Cancer. 1980 Feb;45(3):476–483. doi: 10.1002/1097-0142(19800201)45:3<476::aid-cncr2820450311>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  35. Uchida A., Micksche M. Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432. J Natl Cancer Inst. 1983 Oct;71(4):673–680. [PubMed] [Google Scholar]
  36. Ujiie T. Increased sensitivity of tumor cells to immune defense cells following treatment with antineoplastic agents in vitro. Jpn J Exp Med. 1989 Feb;59(1):17–26. [PubMed] [Google Scholar]
  37. Watanabe Y., Iwa T. Clinical value of immunotherapy with the streptococcal preparation OK-432 in non-small cell lung cancer. J Biol Response Mod. 1987 Apr;6(2):169–180. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES